(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up to 1 billion pounds ($1.33 billion) over the next ten years to broaden ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a fresh partner in mRNA specialist BioNTech. BioNTech plans to invest up to ...

The United Kingdom government has announced its plan to accelerate research into mRNA cancer vaccines in an agreement signed with pharmaceutical company BioNTech. The United Kingdom has signed ...

Overall, BioNTech reported total revenues of € ... European Union and received approval for the same vaccine in the United Kingdom. Over in the United States, BioNTech has initiated a rolling ...

an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1 st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech’s ...

BioNTech also expects new private markets to open up in places like the United Kingdom this year, Richardson noted. For the full year, BioNTech is sticking by its revenue forecast of 2.5 billion ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has entered into an agreement for the global co-development and co-commercialization of German biotech BioNTech’s (Nasdaq: BNTX) investigational ...